Home » Stocks » KLDO

Kaleido Biosciences, Inc. (KLDO)

Stock Price: $6.32 USD 0.50 (8.51%)
Updated May 14, 2021 4:00 PM EDT - Market closed
After-hours: $6.50 +0.19 (2.93%) May 14, 7:58 PM
Market Cap 268.51M
Revenue (ttm) 1.27M
Net Income (ttm) -85.11M
Shares Out 42.52M
EPS (ttm) -2.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $6.32
Previous Close $5.82
Change ($) 0.50
Change (%) 8.51%
Day's Open 5.89
Day's Range 5.80 - 6.69
Day's Volume 260,140
52-Week Range 5.04 - 20.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

--Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109's potential to reduce healthcare utilization and recovery time; initiating IND application to support further development-...

1 week ago - GlobeNewsWire

LEXINGTON, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome to tr...

3 weeks ago - GlobeNewsWire

LEXINGTON, Ma., April 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbi...

1 month ago - GlobeNewsWire

Biotech company Kaleido develops oral therapy for COVID-19

YouTube video

Dan Menichella, Kaleido CEO, joins Yahoo Finance's Anjalee Khemlani, Alexis Christoforous and Kristin Myers to discuss the utilization of oral therapeutic KB109 for COVID-19 and emerging variants.

1 month ago - Yahoo Finance

Kaleido (KLDO) announces impressive results from a study on KB109 in patients with mild-to-moderate COVID-19.

1 month ago - Zacks Investment Research

Kaleido Biosciences Inc (NASDAQ: KLDO) reported positive results from a non-IND study of KB109 in patients with mild-to-moderate COVID-19. KB109 demonstrated an overall favorable safety and tolerability...

1 month ago - Benzinga

KB109 demonstrated favorable safety and tolerability profile

1 month ago - GlobeNewsWire

Topline data from two ongoing COVID-19 studies with KB109 expected in Q1 2021

2 months ago - GlobeNewsWire

LEXINGTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the micro...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...

Other stocks mentioned: AXLA, CDAK, DNLI, EVLO, FHTX, MCRB, MRNA ...
2 months ago - PRNewsWire

Kaleido Biosciences (KLDO) has been struggling lately, but the selling pressure may be coming to an end soon.

2 months ago - Zacks Investment Research

LEXINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...

3 months ago - GlobeNewsWire

Corcept Therapeutics (NASDAQ: CORT) shares were trading lower Tuesday after the company reported preliminary fourth-quarter sales results and issued fiscal year 2021 sales guidance. Corcept Therapeutics...

Other stocks mentioned: ACST, CORT, TMDX
3 months ago - Benzinga

LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...

3 months ago - GlobeNewsWire

LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...

3 months ago - GlobeNewsWire

LEXINGTON, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Keystone Symp...

3 months ago - GlobeNewsWire

Preliminary analysis (n=176) demonstrates favorable safety and tolerability; data provide a strong signal of clinical benefit for subjects reporting one or more comorbidities

4 months ago - GlobeNewsWire

LEXINGTON, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc., (Nasdaq: KLDO) today announced that Dan Menichella, Chief Executive Officer, will present at the 39th Annual J.P. Morgan He...

4 months ago - GlobeNewsWire

Topline data for two studies of KB109 are expected in the first quarter of 2021 Topline data for two studies of KB109 are expected in the first quarter of 2021

4 months ago - GlobeNewsWire

While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: AXLA, CTMX, MGTA
4 months ago - 24/7 Wall Street

LEXINGTON, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that Dan Menichella, Chief Executive Officer, will participate in a fireside chat at the vir...

5 months ago - GlobeNewsWire

- Topline Data for KB109 for the Treatment of Mild-to-Moderate COVID-19 Expected in the First Quarter of 202 1 -

6 months ago - GlobeNewsWire

Ex vivo data from candidate KB109, under evaluation in two clinical studies for COVID-19, to be presented at IDWeek 2020

7 months ago - GlobeNewsWire

LEXINGTON, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced an update to its ongoing COVID-19 clinical development program evaluating KB109 when added t...

7 months ago - GlobeNewsWire

LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat di...

7 months ago - GlobeNewsWire

Why Kaleido Stock Is Taking Off, And Why It Can Go Higher

7 months ago - Seeking Alpha

Top-line safety, tolerability and activity results expected in mid-2021 Top-line safety, tolerability and activity results expected in mid-2021

7 months ago - GlobeNewsWire

LEXINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that Michael Bonney, Executive Chair, will participate in the following upcoming conferen...

8 months ago - GlobeNewsWire

LEXINGTON, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced that data from Microbiome Metabolic Therapy (MMT™) candidate KB174 for hepatic encephalopat...

8 months ago - GlobeNewsWire

- COVID-19 Clinical Development Program Topline Data Readout of Multi-Center Study Expected in Q4 2020 -

9 months ago - GlobeNewsWire

- Second Study Launched in Kaleido’s COVID-19 Clinical Development Program for this Rapidly Growing Patient Population -

9 months ago - GlobeNewsWire

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: AXLA, CTMX, MGTA
9 months ago - 24/7 Wall Street

- Alison Lawton to step down as President and Chief Executive Officer to attend to a family health matter

11 months ago - GlobeNewsWire

LEXINGTON, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat ...

11 months ago - GlobeNewsWire

LEXINGTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat ...

11 months ago - GlobeNewsWire

LEXINGTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat ...

11 months ago - GlobeNewsWire

Kaleido Biosciences, Inc. (KLDO) CEO Alison Lawton on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

- Initiating Clinical Studies of KB109 in Outpatients with Mild-to-Moderate COVID-19; Data Anticipated in Q4 2020 -

1 year ago - GlobeNewsWire

- Top-Line Data from Study of Approximately 350 Patients Expected in Q4 2020 -

1 year ago - GlobeNewsWire

LEXINGTON, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...

1 year ago - GlobeNewsWire

Is (KLDO) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

The Super Bowl of healthcare kicked off early for these companies.

Other stocks mentioned: AMRN, BMY, BX, CLVS, DERM, ISRG, JNJ ...
1 year ago - The Motley Fool

LEXINGTON, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc . (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ ...

1 year ago - GlobeNewsWire

About KLDO

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. The ... [Read more...]

Industry
Biotechnology
IPO Date
Feb 28, 2019
Stock Exchange
NASDAQ
Ticker Symbol
KLDO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for KLDO stock is "Buy." The 12-month stock price forecast is 16.14, which is an increase of 155.58% from the latest price.

Price Target
$16.14
(155.58% upside)
Analyst Consensus: Buy